BUSINESS
Justice B N Srikrishna: the go-to man for the government and corporates
Justice Srikrishna shot to fame after his retirement when he headed the "Srikrishna Commission" that investigated the Bombay communal riots of 1992–93.
BUSINESS
Stern action against Chanda Kochhar a warning to India Inc, say corporate governance experts
JN Gupta, Managing Director of Stakeholders Empowerment Services feels the stern action against ICICI Bank's former chief Chanda Kochhar is a warning for other boards of the corporate world.
BUSINESS
Strides to ramp up sales in US, other regulated markets after Australia biz sale
Strides had a net debt of around Rs 1,820 crore as on December 31, 2018.
BUSINESS
Piramal Enterprises says housing loans to be 10% of advances by end-FY19
Loans to real estate developers which constituted about 78 percent in Q2FY19, has come down to 70 percent in Q3.
BUSINESS
Exclusive | Wockhardt confident of business taking off in 3-5 years aided by India, US and antibiotic portfolio launch
After a disastrous 2017-18, there are signs of recovery in FY19. In 9MFY19, sales grew 9 percent and net loss narrowed to Rs 180 crore from Rs 454 crore from last year.
BUSINESS
This week in Pharma: Government sends mixed signals on drug pricing
With elections just a few months away, it seems that the government may not want to side too much with the industry.
BUSINESS
L&T will stick to FY19 guidance, says studying options after SEBI denies buyback
The country's largest infrastructure company had earlier said that it was expecting a 12-15 percent increase in revenue and 10-12 percent increase in order inflows in the current fiscal.
BUSINESS
Biocon Q3 net profit zooms over twofold to Rs 217.2 cr
Revenues from the biologics vertical, that comprises biosimilars, rose 136 percent to Rs 449 crore driven by the biosimilar Pegfilgrastim gaining market share in the US.
BUSINESS
Lupin's specialty drug Solosec gains traction in US on rising prescriptions
Lupin expects the drug to hit peak sales of $100-$150mn over next 3-4 years, making it a big contributor.
BUSINESS
Allegations on Sun Pharma may tighten scrutiny on related party distribution model in sector
Sun Pharma’s domestic formulation business is entirely routed through a promoter-owned entity called AML, a super stockist that was declared as a related party of the company only during FY18.
BUSINESS
Drug pricing regime: Pharma companies express relief, health activists miffed
Indian pharmaceutical industry was rattled by the decision of former NPPA chairman Bhupendra Singh, who used special powers conferred under Paragraph 19 of the Drug Price Control Order (DPCO) 2013, to slash prices of hundreds of drug formulations, which were not part of National List of Essential Medicines (NLEM).
BUSINESS
Sun Pharma takes steps to limit damage, discontinues AML and unwinds loans
In a filing to stock exchanges on January 22, the company said its distribution related to its domestic formulations business shall be transitioned from AML, the current distributor, to a wholly owned subsidiary of Sun Pharma
BUSINESS
Sun Pharma may discontinue Aditya Medisales super stockist arrangement
Sun Pharma’s domestic formulation business is entirely routed through a promoter-owned entity called AML, a super stockist that was declared as related party of the company only during FY18.
BUSINESS
Weekly blog: Sun Pharma’s governance woes may not fade away soon
The latest whistle-blower complaint alleges large transactions between Aditya Medisales (AML) and Suraksha Realty, controlled by Sun Pharma’s co-promoter Sudhir Valia, out of the money generated from the publicly-listed company
BUSINESS
Dr Reddy's says 50% of US revenues to come from complex drugs by 2021
Dr Reddy’s said it expects specialized channels like oncology clinics, hospitals, and over-the-counter (OTC) to form 60 percent of its trade in next three years.
BUSINESS
Aurobindo buys 7 oncology injectable drugs in $300 million deal
These products had generated $76.4 million in combined sales during the first nine months of 2018.
BUSINESS
Indian pharma market grows 9.4% in 2018 led by medicines for chronic diseases
The growth was aided by sales of cardiac and anti-diabetes medications whose sales grew 11.7 percent to Rs 16,021 crore and 12.9 percent to Rs 12,143 respectively on YoY basis.
BUSINESS
German specialty chemicals maker Evonik bets big on India with evolving environmental standards
Sanjeev Taneja, President and Managing Director of Evonik India says there is much more room for the business to grow led by ever growing middle class and fast paced urbanization, and demand for cleaner, greener and more sustainable products.
BUSINESS
Shalby Hospitals in talks to take control of two hospitals in Delhi, Kolkata for Rs 250 crore
The Delhi hospital has a 150 bed capacity, while Kolkata is a 200 bedded hospital.
BUSINESS
J&J hip implant case: Time to get serious about having robust national clinical registries
It is estimated that close to two lakh knee replacements and 30,000-40,000 hip replacements are done in India, annually. However, the ISHKS registry only received data related to 30,000 surgeries in 2017
BUSINESS
NephroPlus to raise Rs 150 crore for international expansion
So far the company raised Rs 200 crore funding from investors such as International Finance Corporation, SeaLink Capital Partners and Bessemer Venture Capital.
BUSINESS
Private healthcare players welcome government sops to set up hospitals
“At the current package rates offered under Ayushman Bharat, it is not viable to put up hospitals in these places, viability gap funding (VGF) and cross-subsidisation are the way to go,” said Ranjan Pai of Manipal Hospitals.
BUSINESS
J&J faulty hip implants case: Expert committee seeks more time to work on compensation
Nearly 40 victims and their family members have met with the Central Expert Committee to share their concerns regarding the health issues faced by them, compensation formula, the process and related issues with the Committee.
BUSINESS
Government lures private sector with land and funding sops to set up hospitals in tier 2 and 3 cities
The private sector will build, design, finance, manage, operate and maintain with quality standards. Take market risk and provide services at PMJAY rates.
